Human skin replacement - CellTran

Drug Profile

Human skin replacement - CellTran

Alternative Names: LyphoDerm

Latest Information Update: 23 Jan 2013

Price : $50

At a glance

  • Originator CellTran
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Skin ulcer

Most Recent Events

  • 02 Oct 2006 XCELLentis has been acquired and merged into CellTran
  • 13 May 2004 Data from a media release have been added to the Skin Disorders therapeutic trials section
  • 02 Mar 2004 Data from a media release have been added to the Skin Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top